Investing.com - Financial Markets Worldwide

Gilead Sciences resolves civil fraud lawsuit with $202 million settlement

Published 29/04/2025, 19:06
© Reuters
GILD
0.79%
GILD
-2.80%
GILD
-0.77%
GILD
-3.14%

Investing.com -- Gilead Sciences (NASDAQ:GILD), a leading American biopharmaceutical company, has agreed to pay a $202 million settlement to resolve a civil fraud lawsuit. The U.S. attorney’s office in Manhattan stated on Tuesday that the lawsuit accused Gilead of paying kickbacks to doctors who agreed to prescribe its HIV drugs.

The settlement brings an end to claims that Gilead compensated doctors with honoraria, meals, and travel expenses to encourage them to prescribe several of its HIV drugs. These doctors were attendees at Gilead speaker events.

U.S. Attorney Jay Clayton stated that this practice violated the federal False Claims Act. This act was breached as the inducements led to claims being paid by federal healthcare programs. The settlement thus concludes a significant legal challenge for Gilead Sciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.